UChicago Medicine helps bring first-of-its-kind drug for metabolic liver disease to the clinic
University of Chicago Medical CenterResmetirom (Rezdiffra) is the first drug approved for treating MASH, an advanced form of fatty liver disease. UChicago Medicine experts contributed to a recent clinical trial and will begin incorporating the drug into liver disease treatment regimens for eligible patients.